


Curriculum Vitae

Name	MIN-HEE RYU	
Current Position & Affiliation	PROFESSOR ASAN MEDICAL CENTER	
Country	KOREA	

Educational Background

2002.03–2006.02	Ph.D., Postgraduate School, University of Ulsan College of Medicine
1996.03–1998.02	Master of Science, Postgraduate School, Seoul National University
1989.03–1994.02	M.D., College of Medicine, Seoul National University

Professional Experience

2020.03–Present	Chief, Department of Oncology, Asan Medical Center-University of Ulsan College of Medicine
2015.10–Present	Professor, Department of Oncology, Asan Medical Center-University of Ulsan College of Medicine
2009.10–2015.09	Associate Professor, Department of Oncology, Asan Medical Center-University of Ulsan College of Medicine
2004.03–2009.10	Assistant Professor, Department of Oncology, Asan Medical Center-University of Ulsan College of Medicine

Professional Organizations

General Affairs, Korean Cancer Study Group
 Director, Korean Cancer Association
 Director, The Korean Gastric Cancer Association
 Member, Korean Society of Medical Oncology
 Member, American Society of Clinical Oncology
 Member, American Association of Cancer Research
 Member, European Society for Medical Oncology
 Member, Korean Medical Association
 Member, Korean Society of Internal Medicine

Main Scientific Publications

Keun-Wook Lee, Ik-Joo Chung, **Min-Hee Ryu**, Young Iee Park, Byung-Ho Nam, Ho-Suk Oh, Kyung Hee Lee, Hye Sook Han, Bong-Gun Seo, Jae-Cheol Jo, Hyo Rak Lee, Jin Won Kim, Sook Ryun Park, Sang Hee Cho, Yoon-Koo Kang, SOPP study investigators : Multicenter Phase III Trial of S-1 and Cisplatin Versus S-1 and

Oxaliplatin Combination Chemotherapy for First-Line Treatment of Advanced Gastric Cancer (SOPP Trial). *Gastric Cancer*. 2021 Jan;24(1):156-167

Hyungwoo Cho, **Min-Hee Ryu**, Kyu-pyo Kim, Baek-Yeol Ryoo, Sook Ryun Park, Bum Soo Kim, In-Seob Lee, Hee-Sung Kim, Moon-Won Yoo, Jeong Hwan Yook, Seong Tae Oh, Byung Sik Kim, Yoon-Koo Kang : Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis. *Gastric Cancer*. 2017 Nov;20(6):970-977
